AZN AstraZeneca PLC
Stock Price & Overview

$71.13-0.68 (-0.95%)4:00 PM 07/11/25
NASDAQ | $USD | Post-Market: $71.65 +0.52 (+0.73%) 7:39 PM

AZN Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Latest Headlines

Ratings Summary

People Also Follow

Similar to AZN

ETFs Holding AZN

AZN Company Profile

AstraZeneca PLC logo
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Employees
94,300
Founded
1992
Address
  • 1 Francis Crick Avenue
  • Cambridge Biomedical Campus
  • Cambridge, CB2 0AA
  • United Kingdom
Phone Number
44 20 3749 5000

AZN Earnings Per Share

Earnings Estimates

Earnings Revisions

Valuation

Growth

Profitability

Momentum

Capital Structure

AZN Dividend Growth History

AZN Ownership

AZN Peers

Risk

Technicals

AZN Transcripts

Investor Presentations

AZN SEC Filings

AZN Income Statement

AZN Balance Sheet

AZN Cash Flow Statement

AZN Long Term Solvency

AstraZeneca PLC (AZN) Frequently Asked Questions